Interv Akut Kardiol. 2011;10(4):187-190

Medical treatment in coincident valvular heart disease and arterial hypertension

Zdeněk Monhart1, Václav Monhart2
1 Interní oddělení, Nemocnice Znojmo
2 Interní klinika 1. LF UK a ÚVN, Praha

Causal therapy of valvular heart disease falls within the realm of cardiac surgery. A number of patients with valvular heart disease concurrently

suffer from arterial hypertension – they are either patients with a defect that has not yet been indicated for surgery or those

in whom a conservative approach has been chosen due to high surgical risk. When treating arterial hypertension in these patients, it is

often possible to select antihypertensive agents with a certain „added value“ in terms of affecting the symptoms of valvular disease and

left ventricular volumes. These include, in particular, ACE inhibitors in aortic and mitral regurgitation. This group of medications is no

longer prohibited in treating hypertension in patients with aortic stenosis; however, the presumed positive effect on slowing down the

progression of valvular heart disease itself has not been demonstrated.

Keywords: valvular heart disease, arterial hypertension, medication treatment, vasodilator agents

Published: July 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Monhart Z, Monhart V. Medical treatment in coincident valvular heart disease and arterial hypertension. Interv Akut Kardiol. 2011;10(4):187-190.
Download citation

References

  1. Scognamiglio R, Fasoli G, Ponchia A, Dalla-Volta S. Longterm nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation. J Am Coll Cardiol. 1990; 16(2): 424-429. Go to original source... Go to PubMed...
  2. Scognamiglio R, Negut C, Palisi M, Fasoli G, Dalla-Volta S. Long-term survival and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. J Am Coll Cardiol 2005; 45: 1025-1030. Go to original source... Go to PubMed...
  3. Greenberg B, Massie B, Bristow JD, Cheitlin M, Siemienczuk D, Topic N, Wilson RA, Szlachcic J, Thomas D. Long-term vasodilator therapy of chronic aortic insufficiency. A randomized double-blinded, placebo-controlled clinical trial. Circulation. 1988; 78(1): 92-103. Go to original source... Go to PubMed...
  4. Schön HR, Dorn R, Barthel P, Schömig A. Effects of 12 months quinapril therapy in asymptomatic patients with chronic aortic regurgitation. J Heart Valve Dis. 1994; 3(5): 500-509. Go to PubMed...
  5. Wisenbaugh T, Sinovich V, Dullabh A, Sareli P. Six month pilot study of captopril for mildly symptomatic, severe isolated mitral and isolated aortic regurgitation. J Heart Valve Dis. 1994; 3(2): 197-204. Go to PubMed...
  6. Lin M, Chiang HT, Lin SL, Chang MS, Chiang BN, Kuo HW, Cheitlin MD. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol. 1994; 24(4): 1046-1053. Go to original source... Go to PubMed...
  7. Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler Soler J. Long term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005; 353: 1324-1329. Go to original source... Go to PubMed...
  8. Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-268. Go to original source... Go to PubMed...
  9. Antonini-Canterin F, Huang G, Cervesato E, Faggiano P, Pavan D, Piazza R, Nicolosi GL. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension. 2003; 41(6): 1268-1272. Go to original source... Go to PubMed...
  10. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D, Pibarot P. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005; 46(2): 291-298. Go to original source... Go to PubMed...
  11. Vahanian A, Otto CM. Risk stratification of patients with aortic stenosis. Eur. Heart J., 2010; 31(4): 416-423. Go to original source... Go to PubMed...
  12. Pohle K, Mäffert R, Ropers D, Moshage W, Stilianakis N, Daniel WG, Achenbach S. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001; 104(16): 1927-1932. Go to original source... Go to PubMed...
  13. Mohler ER III. Mechanisms of aortic valve calcification. Am J Cardiol 2004; 94: 1396-1402. Go to original source... Go to PubMed...
  14. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA, Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352(23): 2389-2397. Go to original source... Go to PubMed...
  15. Rosseb? AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R, SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359(13): 1343-1356. Go to original source... Go to PubMed...
  16. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010; 121(2): 306-314. Go to original source... Go to PubMed...
  17. O'Brien KD, Probstfield JL, Caulfield MT, Nasir K, Takasu J, Shavelle DM, Wu AH, Zhao XQ, Budoff MJ. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005; 165: 858-862. Go to original source... Go to PubMed...
  18. Routledge HC, Townend JN. ACE inhibition in aortic stenosis: dangerous medicine or golden opportunity? J Hum Hypertens. 2001; 15(10): 659-667. Go to original source... Go to PubMed...
  19. O'Brien KD, Zhao XQ, Shavelle DM, Caulfield MT, Letterer RA, Kapadia SR, Probstfield JL, Otto CM. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004; 52(3): 185-191. Go to original source... Go to PubMed...
  20. Chambers J. The left ventricle in aortic stenosis: evidence for the use of ACE inhibitors. Heart. 2006; 92(3): 420-423. Go to original source... Go to PubMed...
  21. Zybach-Benz RE, Aeschbacher BC, Schwerzmann M. Impact of left ventricular hypertrophy late after aortic valve replacement for aortic stenosis on cardiovascular morbidity and mortality. Int J Cardiol. 2006; 109(1): 41-47. Go to original source... Go to PubMed...
  22. Dahl JS, Videbaek L, Poulsen MK, Pellikka PA, Veien K, Andersen LI, Haghfelt T, M?ller JE. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol. 2010; 106(5): 713-719. Go to original source... Go to PubMed...
  23. Imanaka K, Kohmoto O, Nishimura S, Yokote Y, Kyo S. Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis. Eur J Cardiothorac Surg. 2005; 27(6): 994-999. Go to original source... Go to PubMed...
  24. Ciulla MM, Paliotti R, Esposito A, Cuspidi C, Muiesan ML, Rosei EA, Magrini F, Zanchetti A. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensinconverting enzyme inhibitor, enalapril. J Hypertens. 2009; 27(3): 626-632. Go to original source... Go to PubMed...
  25. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009; 373(9667): 956-966. Go to original source... Go to PubMed...
  26. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, 2006 Writing Committee Members, American College of Cardiology/ American Heart Association Task Force. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008; 118(8): 887-896. Go to original source... Go to PubMed...
  27. Ferencik M, Pape LA. Changes in size of ascending aorta and aortic valve function with time in patients with congenitally bicuspid aortic valves. Am J Cardiol 2003; 92(1): 43-46. Go to original source... Go to PubMed...
  28. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994; 330(19): 1335-1341. Go to original source... Go to PubMed...
  29. Ahimastos AA, Aggarwal A, D'Orsa KM, Formosa MF, White AJ, Savarirayan R, Dart AM, Kingwell BA. Effect of perindopril on large artery stiffness and aortic root diameter in patients with Marfan syndrome: a randomized controlled trial. JAMA. 2007; 298(13): 1539-1547. Go to original source... Go to PubMed...
  30. Williams A, Davies S, Stuart AG, Wilson DG, Fraser AG. Medical treatment of Marfan syndrome: a time for change. Heart. 2008; 94(4): 414-421. Go to original source... Go to PubMed...
  31. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Dietz HC; GenTAC Consortium. Circulating transforming growth factor-beta in Marfan syndrome. Circulation. 2009; 120(6): 526-532. Go to original source... Go to PubMed...
  32. Radonic T, de Witte P, Baars MJ, Zwinderman AH, Mulder BJ, Groenink M; COMPARE study group. Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials. 2010; 11: 3. Go to original source... Go to PubMed...
  33. Detaint D, Aegerter P, Tubach F, Hoffman I, Plauchu H, Dulac Y, Faivre LO, Delrue MA, Collignon P, Odent S, Tchitchinadze M, Bouffard C, Arnoult F, Gautier M, Boileau C, Jondeau G. Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome. Arch Cardiovasc Dis. 2010; 103(5): 317-325. Go to original source... Go to PubMed...
  34. Möberg K, De Nobele S, Devos D, Goetghebeur E, Segers P, Trachet B, Vervaet C, Renard M, Coucke P, Loeys B, De Paepe A, De Backer J. The Ghent Marfan Trial - A randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with ?-blockers. Int J Cardiol. 2011. [Epub ahead of print]. Go to original source...
  35. Levine HJ, Gaasch WH. Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol. 1996; 28(5): 1083-1091. Go to original source... Go to PubMed...
  36. Marcotte F, Honos GN, Walling AD, Beauvais D, Blais MJ, Daoust C, Lisbona A, McCans JL. Effect of angiotensin-converting enzyme inhibitor therapy in mitral regurgitation with normal left ventricular function. Can J Cardiol. 1997; 13(5): 479-485.
  37. Grayburn PA. Vasodilator therapy for chronic aortic and mitral regurgitation. Am J Med Sci 2000; 320: 202-208. Go to original source...
  38. Iung B, Gohlke-Bärwolf C, Tornos P, Tribouilloy C, Hall R, Butchart E, Vahanian A, Working Group on Valvular Heart Disease. Recommendations on the management of the asymptomatic patient with valvular heart disease. Eur Heart J. 2002; 23(16): 1253-1266. Go to original source... Go to PubMed...
  39. Schön HR, Schröter G, Barthel P, Schömig A. Quinapril therapy in patients with chronic mitral regurgitation. J Heart Valve Dis. 1994; 3(3): 303-312. Go to PubMed...
  40. Levine AB, Muller C, Levine TB. Effects of high-dose lisinopril-isosorbide dinitrate on severe mitral regurgitation and heart failure remodeling. Am J Cardiol. 1998; 82(10): 1299-1301. Go to original source... Go to PubMed...
  41. Bhatia ML, Shrivastava S, Roy SB. Immediate haemodynamic effects of a beta adrenergic blocking agent - propranolo - in mitral stenosis at fixed heart rates. Br Heart J 1972; 34: 638-644. Go to original source... Go to PubMed...
  42. Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology 2002; 53: 575-578. Go to original source... Go to PubMed...
  43. Bruce CJ, Nishimura RA. Newer advances in the diagnosis and treatment of mitral stenosis. Curr Probl Cardiol. 1998; 23(3): 125-192. Go to original source... Go to PubMed...




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.